Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · IEX Real-Time Price · USD
5.87
-0.14 (-2.33%)
Jul 22, 2024, 10:12 AM EDT - Market open
Candel Therapeutics Employees
Candel Therapeutics had 42 employees as of December 31, 2023. The number of employees decreased by 34 or -44.74% compared to the previous year.
Employees
42
Change (1Y)
-34
Growth (1Y)
-44.74%
Revenue / Employee
n/a
Profits / Employee
-$889,643
Market Cap
181.51M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 42 | -34 | -44.74% |
Dec 31, 2022 | 76 | 11 | 16.92% |
Dec 31, 2021 | 65 | 24 | 58.54% |
Dec 31, 2020 | 41 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Accuray | 1,024 |
Metagenomi | 236 |
Seres Therapeutics | 233 |
Puma Biotechnology | 185 |
OptimizeRx | 136 |
Biomea Fusion | 103 |
XBiotech | 82 |
Fennec Pharmaceuticals | 29 |
CADL News
- 5 weeks ago - Candel Therapeutics to Join Russell 3000® Index - GlobeNewsWire
- 7 weeks ago - FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma - GlobeNewsWire
- 2 months ago - Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Candel Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting - GlobeNewsWire
- 2 months ago - Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 3 months ago - Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting - GlobeNewsWire
- 3 months ago - Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer - GlobeNewsWire